GlassScriptPhysician profile
John J Dagianis
NPI 1972508026
$8,515.39
in general payments reported to CMS, 2019-2025
34 companies · $1,337 in 2025
The $1,337 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,230 · 2020: $424 · 2021: $519 · 2022: $1,142 · 2023: $1,707 · 2024: $2,157 · 2025: $1,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,805 · Entertainment: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,805.37 |
| Entertainment | $395.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,486.19 | 2019-2025 | Clareon, Rocklatan, Unity |
| Bausch & Lomb Americas INC. | $902.58 | 2022-2025 | Miebo, Xiidra, Infuse |
| Optos, INC. | $711.29 | 2022-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Oyster Point Pharma, INC. | $520.06 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $428.02 | 2019-2021 | |
| Abbvie INC. | $411.74 | 2022-2025 | Ozurdex, Alphagan P, Lumigan |
| Horizon Therapeutics Plc | $364.53 | 2022-2023 | Tepezza |
| Mallinckrodt Hospital Products INC. | $311.41 | 2024-2025 | Acthar |
| Amgen INC. | $267.96 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $263.72 | 2019-2021 | |
| Ivantis, INC | $249.99 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $192.47 | 2019-2025 | Cequa |
| Kala Pharmaceuticals, INC. | $167.66 | 2019-2021 | |
| Sight Sciences, INC. | $154.35 | 2019-2024 | Tearcare System |
| Regeneron Healthcare Solutions, INC. | $143.09 | 2024-2025 | Eylea Hd |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $137.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $126.49 | 2019-2022 | |
| Astellas Pharma US INC | $105.34 | 2025 | Izervay |
| Iridex Corporation | $69.88 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $63.84 | 2025 | Xdemvy |
| Optovue, INC. | $63.42 | 2019 | |
| Dompe US, INC. | $45.05 | 2020-2024 | Oxervate |
| Biotissue Holdings INC. | $38.92 | 2019-2025 | |
| Johnson & Johnson Vision Care, INC. | $38.56 | 2019 | |
| Omeros Corporation | $37.56 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $34.47 | 2025 | Syfovre |
| Allergan, INC. | $31.71 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $25.28 | 2025 | Purified Cortrophin Gel |
| Glaukos Corporation | $24.91 | 2024 | Idose |
| Coopervision INC. | $23.70 | 2019 | |
| Harrow Eye, LLC | $20.06 | 2023 | Iheezo |
| Rayner Intraocular Lenses Limited | $19.04 | 2023 | Omidria, Rayone Emv, Rayone Aspheric |
| Eyepoint US, INC. | $18.79 | 2019 | |
| Thea Pharma INC. | $15.98 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dagianis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.